JP2000500662A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2000500662A5 JP2000500662A5 JP1998508568A JP50856898A JP2000500662A5 JP 2000500662 A5 JP2000500662 A5 JP 2000500662A5 JP 1998508568 A JP1998508568 A JP 1998508568A JP 50856898 A JP50856898 A JP 50856898A JP 2000500662 A5 JP2000500662 A5 JP 2000500662A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR96/09584 | 1996-07-30 | ||
FR9609584A FR2751879B1 (fr) | 1996-07-30 | 1996-07-30 | Composition pharmaceutique contre les tumeurs et infections a papillomavirus |
PCT/FR1997/001412 WO1998004705A1 (fr) | 1996-07-30 | 1997-07-29 | Composition pharmaceutique contre les tumeurs et infections a papillomavirus |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007092639A Division JP4198735B2 (ja) | 1996-07-30 | 2007-03-30 | パピローマウイルス腫瘍および感染を治療するための医薬組成物 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2000500662A JP2000500662A (ja) | 2000-01-25 |
JP2000500662A5 true JP2000500662A5 (ja) | 2004-11-18 |
JP4070815B2 JP4070815B2 (ja) | 2008-04-02 |
Family
ID=9494633
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50856898A Expired - Fee Related JP4070815B2 (ja) | 1996-07-30 | 1997-07-29 | パピローマウイルス腫瘍および感染を治療するための医薬組成物 |
JP2007092639A Expired - Fee Related JP4198735B2 (ja) | 1996-07-30 | 2007-03-30 | パピローマウイルス腫瘍および感染を治療するための医薬組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007092639A Expired - Fee Related JP4198735B2 (ja) | 1996-07-30 | 2007-03-30 | パピローマウイルス腫瘍および感染を治療するための医薬組成物 |
Country Status (12)
Country | Link |
---|---|
EP (2) | EP1149910B1 (ja) |
JP (2) | JP4070815B2 (ja) |
AT (2) | ATE265535T1 (ja) |
AU (1) | AU736720B2 (ja) |
CA (1) | CA2234263C (ja) |
DE (2) | DE69728914T2 (ja) |
DK (2) | DK1149910T3 (ja) |
ES (2) | ES2163795T5 (ja) |
FR (1) | FR2751879B1 (ja) |
HK (1) | HK1043809B (ja) |
PT (2) | PT862634E (ja) |
WO (1) | WO1998004705A1 (ja) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2229955C (en) | 1998-02-20 | 2003-12-09 | Medigene Gmbh | Papilloma virus capsomere vaccine formulations and methods of use |
US7494658B2 (en) | 1998-02-20 | 2009-02-24 | Medigene Ag | Papilloma virus truncated L1 protein and fusion protein constructs |
US20020039584A1 (en) | 1998-02-20 | 2002-04-04 | Medigene Ag | Papilloma virus capsomere vaccine formulations and methods of use |
US7182947B2 (en) | 1998-02-20 | 2007-02-27 | Medigene Ag | Papillomavirus truncated L1 protein and fusion protein constructs |
US6926897B1 (en) | 1998-03-24 | 2005-08-09 | Medigene Aktiengesellschaft | Medicament for the avoidance or treatment of papillomavirus-specific tumour |
CA2335506A1 (en) * | 1998-06-26 | 2000-01-06 | Aventis Pasteur | Mucosal targeting immunisation |
DK2029756T3 (en) | 2006-06-20 | 2017-02-13 | Transgene Sa | PROCEDURE FOR PREPARING POXVIRA AND POXVIRUS COMPOSITIONS |
DK2382474T3 (en) | 2009-01-20 | 2015-04-07 | Transgene Sa | SOLUBLE ICAM-1 as a biomarker FOR PREDICTION OF THERAPEUTIC RESPONSE |
EP2411815B1 (en) | 2009-03-24 | 2015-11-11 | Transgene SA | Biomarker for monitoring patients |
BRPI1010512A2 (pt) | 2009-04-17 | 2016-03-15 | Transgène S A | "método ex vivo para avaliar a eficácia de um tratamento envolvendo a administração de uma composição imunogênica a um paciente, e, uso de níveis de linfócitos t ativados (cd3 + cd69+) como um biomarcador" |
EP2429579A1 (en) | 2009-05-12 | 2012-03-21 | Transgene SA | Immortalized avian cell lines and use thereof |
AU2010270313B2 (en) | 2009-07-10 | 2014-05-22 | Transgene Sa | Biomarker for selecting patients and related methods |
TW201109440A (en) | 2009-07-21 | 2011-03-16 | Transgene Sa | Enzymatic composition for the digestion of chicken embryos |
TWI690322B (zh) | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
WO2016087457A1 (en) | 2014-12-01 | 2016-06-09 | Transgene Sa | Stable liquid vaccinia virus formulations |
FR3042121A1 (fr) * | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
JP2020519666A (ja) | 2017-05-15 | 2020-07-02 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | 安定性のウイルス含有組成物 |
AU2018270375A1 (en) | 2017-05-15 | 2019-10-31 | Bavarian Nordic A/S | Stable virus-containing composition |
EP3847246A1 (en) | 2018-09-06 | 2021-07-14 | Bavarian Nordic A/S | Storage improved poxvirus compositions |
IL296250A (en) | 2020-03-12 | 2022-11-01 | Bavarian Nordic As | The compounds that improve the stability of the smallpox virus |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2643817B1 (fr) * | 1989-03-06 | 1993-12-17 | Transgene Sa | Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus |
CA2038581A1 (en) † | 1990-03-20 | 1991-09-21 | Martin Muller | Seroreactive epitopes of human papillomavirus (hpv) 16 proteins |
GB9113809D0 (en) * | 1991-06-26 | 1991-08-14 | Cancer Res Campaign Tech | Papillomavirus l2 protein |
EP1298211B1 (en) * | 1991-07-19 | 2006-07-12 | The University Of Queensland | Polynucleotide segment of HPV16 Genome |
US5618536A (en) * | 1992-09-03 | 1997-04-08 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric papillomavirus-like particles |
GB9306731D0 (en) * | 1993-03-31 | 1993-05-26 | Cancer Res Campaign Tech | Vaccines |
IL113817A (en) * | 1994-06-30 | 2001-03-19 | Merck & Co Inc | Polynucleotide for vaccination against the umbilical cord virus |
AU712714B2 (en) * | 1994-10-03 | 1999-11-11 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule B7 gene in a recombinant virus expressing system |
GB9505784D0 (en) * | 1995-03-22 | 1995-05-10 | Lynxvale Ltd | Anti-tumour treatment |
FR2749323B1 (fr) * | 1996-06-04 | 1998-07-10 | Pasteur Merieux Serums Vacc | Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique |
-
1996
- 1996-07-30 FR FR9609584A patent/FR2751879B1/fr not_active Expired - Fee Related
-
1997
- 1997-07-29 ES ES97935646T patent/ES2163795T5/es not_active Expired - Lifetime
- 1997-07-29 AU AU38552/97A patent/AU736720B2/en not_active Ceased
- 1997-07-29 PT PT97935646T patent/PT862634E/pt unknown
- 1997-07-29 EP EP01109013A patent/EP1149910B1/fr not_active Expired - Lifetime
- 1997-07-29 DE DE69728914T patent/DE69728914T2/de not_active Expired - Lifetime
- 1997-07-29 JP JP50856898A patent/JP4070815B2/ja not_active Expired - Fee Related
- 1997-07-29 AT AT01109013T patent/ATE265535T1/de active
- 1997-07-29 DK DK01109013T patent/DK1149910T3/da active
- 1997-07-29 ES ES01109013T patent/ES2215805T3/es not_active Expired - Lifetime
- 1997-07-29 WO PCT/FR1997/001412 patent/WO1998004705A1/fr active IP Right Grant
- 1997-07-29 AT AT97935646T patent/ATE205881T1/de active
- 1997-07-29 PT PT01109013T patent/PT1149910E/pt unknown
- 1997-07-29 EP EP97935646A patent/EP0862634B2/fr not_active Expired - Lifetime
- 1997-07-29 CA CA002234263A patent/CA2234263C/fr not_active Expired - Fee Related
- 1997-07-29 DE DE69706825T patent/DE69706825T3/de not_active Expired - Lifetime
- 1997-07-29 DK DK97935646T patent/DK0862634T4/da active
-
2002
- 2002-04-30 HK HK02103266.9A patent/HK1043809B/zh not_active IP Right Cessation
-
2007
- 2007-03-30 JP JP2007092639A patent/JP4198735B2/ja not_active Expired - Fee Related